Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) saw an uptick in trading volume on Monday. 112,449 shares changed hands during mid-day trading, an increase of 48% from the average daily volume of 76,050 shares. The stock last traded at $4.1780 and had previously closed at $3.89.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Hold rating. According to MarketBeat, the stock currently has a consensus rating of “Hold”.
View Our Latest Research Report on Anbio Biotechnology
Anbio Biotechnology Stock Performance
The company’s 50-day moving average is $5.07 and its 200-day moving average is $16.39.
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Read More
- Five stocks we like better than Anbio Biotechnology
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
